Pharmacological antagonism of EP2 receptor does not modify basal cardiovascular and respiratory function, blood cell counts, and bone morphology in animal models.

[1]  Jiawang Liu,et al.  EP2 Antagonists (2011-2021): A Decade's Journey from Discovery to Therapeutics. , 2021, Journal of medicinal chemistry.

[2]  R. Dingledine,et al.  Inhibition of the prostaglandin EP2 receptor prevents long-term cognitive impairment in a model of systemic inflammation , 2020, Brain, behavior, & immunity - health.

[3]  Jianxiong Jiang,et al.  Inhibiting the PGE2 Receptor EP2 Mitigates Excitotoxicity and Ischemic Injury. , 2020, ACS pharmacology & translational science.

[4]  Jianxiong Jiang,et al.  COX‐2/PGE2 axis regulates hippocampal BDNF/TrkB signaling via EP2 receptor after prolonged seizures , 2020, Epilepsia open.

[5]  R. Dingledine,et al.  A rat model of organophosphate-induced status epilepticus and the beneficial effects of EP2 receptor inhibition , 2020, Neurobiology of Disease.

[6]  A. Rojas,et al.  Potent, selective, water soluble, brain-permeable EP2 receptor antagonist for use in central nervous system disease models. , 2020, Journal of medicinal chemistry.

[7]  R. Dingledine,et al.  A novel microglia cell line expressing the human EP2 receptor. , 2019, ACS chemical neuroscience.

[8]  A. Shimamoto,et al.  Molecular mechanisms underlying prostaglandin E2-exacerbated inflammation and immune diseases. , 2019, International immunology.

[9]  E. Zhang,et al.  Small‐molecule inhibition of prostaglandin E receptor 2 impairs cyclooxygenase‐associated malignant glioma growth , 2019, British journal of pharmacology.

[10]  R. Dingledine,et al.  Suppressing pro-inflammatory prostaglandin signaling attenuates excitotoxicity-associated neuronal inflammation and injury , 2019, Neuropharmacology.

[11]  S. Narumiya,et al.  T cell–intrinsic prostaglandin E2-EP2/EP4 signaling is critical in pathogenic TH17 cell–driven inflammation , 2019, The Journal of allergy and clinical immunology.

[12]  R. Dingledine,et al.  The COX-2/prostanoid signaling cascades in seizure disorders , 2018, Expert opinion on therapeutic targets.

[13]  D. Weiss,et al.  The cofilin phosphatase slingshot homolog 1 restrains angiotensin II-induced vascular hypertrophy and fibrosis in vivo , 2018, Laboratory Investigation.

[14]  Y. T. Yeung,et al.  Signaling Pathways in Inflammation and Anti-inflammatory Therapies. , 2018, Current pharmaceutical design.

[15]  Jianxiong Jiang,et al.  Cyclooxygenase-2 contributes to oxidopamine-mediated neuronal inflammation and injury via the prostaglandin E2 receptor EP2 subtype , 2017, Scientific Reports.

[16]  P. Saunders,et al.  EP2 receptor antagonism reduces peripheral and central hyperalgesia in a preclinical mouse model of endometriosis , 2017, Scientific Reports.

[17]  R. Dingledine,et al.  Inhibition of the prostaglandin E2 receptor EP2 prevents status epilepticus-induced deficits in the novel object recognition task in rats , 2016, Neuropharmacology.

[18]  K. Andreasson,et al.  Inflammatory Cyclooxygenase Activity and PGE2 Signaling in Models of Alzheimer’s Disease , 2015, Current immunology reviews.

[19]  R. Dingledine,et al.  Inhibition of the prostaglandin EP2 receptor is neuroprotective and accelerates functional recovery in a rat model of organophosphorus induced status epilepticus , 2015, Neuropharmacology.

[20]  R. Dingledine,et al.  Therapeutic window for cyclooxygenase-2 related anti-inflammatory therapy after status epilepticus , 2015, Neurobiology of Disease.

[21]  H. Brown,et al.  Prostaglandin signaling suppresses beneficial microglial function in Alzheimer's disease models. , 2015, The Journal of clinical investigation.

[22]  T. Ganesh.  Prostanoid receptor EP2 as a therapeutic target. , 2014, Journal of medicinal chemistry.

[23]  R. Dingledine,et al.  Lead Optimization Studies of Cinnamic Amide EP2 Antagonists , 2014, Journal of medicinal chemistry.

[24]  N. Pullen,et al.  Characterization of the EP receptor subtype that mediates the inhibitory effects of prostaglandin E2 on IgE‐dependent secretion from human lung mast cells , 2013, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[25]  S. Narumiya,et al.  Prostaglandin E2 promotes Th1 differentiation via synergistic amplification of IL-12 signalling by cAMP and PI3-kinase , 2013, Nature Communications.

[26]  F. Dudek,et al.  Inhibition of the prostaglandin receptor EP2 following status epilepticus reduces delayed mortality and brain inflammation , 2013, Proceedings of the National Academy of Sciences.

[27]  R. Dingledine,et al.  Role of Prostaglandin Receptor EP2 in the Regulations of Cancer Cell Proliferation, Invasion, and Inflammation , 2013, The Journal of Pharmacology and Experimental Therapeutics.

[28]  J. Toguchida,et al.  Prostaglandin E2 receptor type 2-selective agonist prevents the degeneration of articular cartilage in rabbit knees with traumatic instability , 2011, Arthritis research & therapy.

[29]  L. Raisz,et al.  Prostaglandins in bone: bad cop, good cop? , 2010, Trends in Endocrinology & Metabolism.

[30]  R. Guldberg,et al.  Rescue of impaired fracture healing in COX-2-/- mice via activation of prostaglandin E2 receptor subtype 4. , 2009, The American journal of pathology.

[31]  S. Narumiya,et al.  Prostaglandin E2–EP4 signaling promotes immune inflammation through TH1 cell differentiation and TH17 cell expansion , 2009, Nature Medicine.

[32]  T. Montine,et al.  The prostaglandin E2 EP2 receptor accelerates disease progression and inflammation in a model of amyotrophic lateral sclerosis , 2008, Annals of neurology.

[33]  S. Narumiya,et al.  Involvement of Prostaglandin E2 in Production of Amyloid-β Peptides Both in Vitro and in Vivo* , 2007, Journal of Biological Chemistry.

[34]  A. Sacchetti,et al.  EP2 prostanoid receptor promotes squamous cell carcinoma growth through epidermal growth factor receptor transactivation and iNOS and ERK1/2 pathways , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[35]  R. Tuma,et al.  The Proinflammatory Effect of Prostaglandin E2 in Experimental Inflammatory Bowel Disease Is Mediated through the IL-23→IL-17 Axis1 , 2007, The Journal of Immunology.

[36]  A. Almudevar,et al.  Deletion of prostaglandin E2 EP2 receptor protects against ultraviolet-induced carcinogenesis, but increases tumor aggressiveness. , 2007, The Journal of investigative dermatology.

[37]  T. Montine,et al.  Journal of Neuroinflammation Prostaglandin E 2 Receptor Subtype 2 (ep2) Regulates Microglial Activation and Associated Neurotoxicity Induced by Aggregated Α-synuclein , 2022 .

[38]  A. Pozzi,et al.  EP2, a receptor for PGE2, regulates tumor angiogenesis through direct effects on endothelial cell motility and survival , 2006, Oncogene.

[39]  S. Fischer,et al.  Overexpression of the prostaglandin E2 receptor EP2 results in enhanced skin tumor development , 2006, Oncogene.

[40]  S. Narumiya,et al.  Prostacyclin-IP signaling and prostaglandin E2-EP2/EP4 signaling both mediate joint inflammation in mouse collagen-induced arthritis , 2006, The Journal of experimental medicine.

[41]  G. Scadding,et al.  Aspirin-sensitive rhinosinusitis is associated with reduced E-prostanoid 2 receptor expression on nasal mucosal inflammatory cells. , 2006, The Journal of allergy and clinical immunology.

[42]  T. Montine,et al.  Deletion of the Prostaglandin E2 EP2 Receptor Reduces Oxidative Damage and Amyloid Burden in a Model of Alzheimer's Disease , 2005, The Journal of Neuroscience.

[43]  T. Montine,et al.  Microglial EP2 is critical to neurotoxicity from activated cerebral innate immunity , 2005, Glia.

[44]  T. Montine,et al.  Microglia Lacking E Prostanoid Receptor Subtype 2 Have Enhanced Aβ Phagocytosis yet Lack Aβ-Activated Neurotoxicity , 2005 .

[45]  T. Mak,et al.  Prostaglandin E(2) inhibits fibroblast migration by E-prostanoid 2 receptor-mediated increase in PTEN activity. , 2005, American journal of respiratory cell and molecular biology.

[46]  J. Menani,et al.  Central moxonidine on salivary gland blood flow and cardiovascular responses to pilocarpine , 2003, Brain Research.

[47]  S. Vukicevic,et al.  An EP2 receptor-selective prostaglandin E2 agonist induces bone healing , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[48]  T. Montine,et al.  Neuronal oxidative damage from activated innate immunity is EP2 receptor‐dependent , 2002, Journal of neurochemistry.

[49]  R. Breyer,et al.  Printed in U.S.A. Copyright © 2000 by The Endocrine Society Knockout of the Murine Prostaglandin EP 2 Receptor Impairs Osteoclastogenesis in Vitro* , 2022 .

[50]  H. S. Kim,et al.  Reproductive failure and reduced blood pressure in mice lacking the EP2 prostaglandin E2 receptor. , 1999, The Journal of clinical investigation.

[51]  Mark A. Magnuson,et al.  Salt–sensitive hypertension and reduced fertility in mice lacking the prostaglandin EP2 receptor , 1999, Nature Medicine.

[52]  R. Weller,et al.  Prostaglandin E2 stimulates adaptive IL‐22 production and promotes allergic contact dermatitis , 2018, The Journal of allergy and clinical immunology.

[53]  A. Baccarelli,et al.  Impaired E Prostanoid2 Expression and Resistance to Prostaglandin E2 in Nasal Polyp Fibroblasts from Subjects with Aspirin-Exacerbated Respiratory Disease. , 2016, American journal of respiratory cell and molecular biology.

[54]  J. Mullol,et al.  Low E-prostanoid 2 receptor levels and deficient induction of the IL-1β/IL-1 type I receptor/COX-2 pathway: Vicious circle in patients with aspirin-exacerbated respiratory disease. , 2016, The Journal of allergy and clinical immunology.

[55]  S. Narumiya,et al.  Prostaglandin E2 is required for ultraviolet B-induced skin inflammation via EP2 and EP4 receptors , 2007, Laboratory Investigation.

[56]  D. Kimmel,et al.  Effects of long-term daily administration of prostaglandin-E2 on maintaining elevated proximal tibial metaphyseal cancellous bone mass in male rats , 2004, Calcified Tissue International.

[57]  H. Szeto,et al.  Central muscarinic modulation of fetal blood pressure and heart rate. , 1990, Journal of developmental physiology.

[58]  U. Trendelenburg.  The pressor response of the cat to histamine and pilocarpine. , 1961, The Journal of pharmacology and experimental therapeutics.